Radar · Life Sciences in Shenzhen
Best Life Sciences Companies in Shenzhen, China
The 124 best Life Sciences companies in Shenzhen, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MGI.
By Rohit KhannaTrends & Stories
124companies tracked
$3.4Bdisclosed funding
1unicorns
59have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SHENZHEN
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
40%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2017median founding year
271kcombined LinkedIn audience
89%of audience held by top 3
1companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Shenzhen
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MGI Provider of gene sequencing instruments, reagents, equipment, and related products | $1.0B | 72 mo ago | Series B | Liu Siqi Co-Founder | 2,805 | 19 patents Integrated microfluidic sequencing devices with temperature control, reagent cartridges, and chemiluminescent reagents | — |
| 2 | ICarbonX 🦄 Provider of bioinformatic platforms for health management and drug development 67Moat top 26%Funding top 27%Talent top 28%AI top 30% All 8 signals ▾Moattop 26% Fundingtop 27% Talenttop 28% AItop 30% Markettop 38% Globalbottom 48% Newsbottom 27% Techbottom 21% Moat: Editorial + unicorn rating 9/10 · Unicorn Funding: Raised $366M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $366M | 62 mo ago | Series D | Yingrui Li Co-Founder & Chief Scientist | 300 | — | 2 partnerships |
| 3 | Shenzhen Jingfeng Medical Technology Developer of surgical robot instruments | $307M | 55 mo ago | Public | Gao Yuanqian Co-Founder | — | — | — |
| 4 | BGI Provider of services in genome sequencing | $300M | 63 mo ago | Public | Wang Jian Chairman & CEO | 7 | — | 1 launch · 1 partnership |
| 5 | Cornerstone Robotics Developer of medical robotic devices for rehabilitation and surgery 21Funding top 16%Moat top 31%Talent bottom 49%News bottom 41% All 7 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Newsbottom 41% Globalbottom 38% Marketbottom 28% Techbottom 22% Funding: Raised $189M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 21/100 | $189M | 7 mo ago | Series D | Zerui Wang Co-Founder | — | — | 1 launch |
| 6 | GeneMind Developer of genome sequencing technology for molecular diagnosis | $158M | 34 mo ago | Series C | Yan Qin CEO | — | — | 1 launch |
| 7 | Silicon-based Provider of designing, manufacturing, regulatory affair, and other services for medical device industry | $150M | 42 mo ago | Series D | — | 700 | 8 patents Thermal management and power distribution hardware for high‑density server data centers | 3 job openings · 1 partnership |
| 8 | Innorna Developer of RNA medicine technologies, including delivery and mRNA engineering | $120M | 50 mo ago | Series B | Li Linxian CEO | — | 2 patents Lipid nanoparticle drug delivery systems and amino lipid synthesis methods | — |
| 9 | Xbiome Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome 64AI top 20%Funding top 36%Moat top 38%Market top 49% All 5 signals ▾AItop 20% Fundingtop 36% Moattop 38% Markettop 49% Globalbottom 36% AI: Classified as an AI company Funding: Raised $108M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $108M | 53 mo ago | Series B | — | 63 | — | — |
| 10 | China Resources Bio-Pharmaceutic Developer of protein and antibody drugs to treat multiple diseases | $89M | 41 mo ago | Series B | — | 400 | — | — |
| 11 | Lifetech Scientific Corporation Interventional medical devices to treat cardiovascular and peripheral vascular diseases. | $66M | 164 mo ago | Public | — | 1,391 | 5 patents Cardiac left atrial appendage occlusion devices and degradable iron alloy support structures | — |
| 12 | Shenzhen Shenyan Biotechnology Developer of automated cell processing system | $57M | 28 mo ago | Series B | Xue Bofu Founder | — | — | — |
| 13 | Yuanhua Intelligent Technology Developer of surgery assistant robotic system | $45M | 53 mo ago | Series B | Meng Aili Founder | — | — | — |
| 14 | Leman Biotech Develope rof AI-based platform for cancer immunotherapy 21AI top 30%Talent top 38%Funding top 39%Global bottom 29% All 6 signals ▾AItop 30% Talenttop 38% Fundingtop 39% Globalbottom 29% Marketbottom 25% Techbottom 15% AI: Classified as an AI company · Product described with: ai-based Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $43M | 3 mo ago | Series A | Li Tang Co-Founder | — | — | — |
| 15 | Insight Lifetech Developer of ultrathin pressure microcatheter for coronary stenosis. | $43M | 65 mo ago | Public | Liang Song Co-Founder | 522 | 21 patents Intravascular microcatheter devices and real-time ultrasound imaging/pressure analytics | 1 launch |
| 16 | Haplox Provider of ultra sensitive liquid biopsy tests for cancer | $39M | 46 mo ago | Series D | Fang Wen Co-Founder & COO | 724 | — | — |
| 17 | Shenzhen Target Developer of therapies for treating various types of cancer | $36M | 69 mo ago | Series A | Wang Yihan Founder & CEO | 72 | — | — |
| 18 | Aibo Medical Provider of vascular interventional surgery robot system development services | $33M | 36 mo ago | Seed | Shuxiang Guo Founder | — | — | — |
| 19 | Vivolight Developer of optical coherence tomography for coronary functional evaluation 21Funding top 33%Talent top 38%Global bottom 36%Tech bottom 34% All 5 signals ▾Fundingtop 33% Talenttop 38% Globalbottom 36% Techbottom 34% Marketbottom 25% Funding: Raised $28.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $28M | 3 mo ago | Seed | Zhu Rui Founder & CEO | — | — | — |
| 20 | GoodCell Stem cell storage service provider | $24M | 68 mo ago | Deadpooled | — | 50 | — | — |
| 21 | Aegicare Developer of NGS-based genetic diagnostic devices | $20M | 65 mo ago | Series B | Yang Li Founder & CEO | 9 | — | — |
| 22 | Biocomma Provides molecular biology products | $15M | 55 mo ago | Series A | Gaoming Chen CEO | — | — | — |
| 23 | InnerMedical Developer of minimally invasive interventional imaging equipment | $15M | 61 mo ago | Series C | Xiaosong Bai Founder & CEO | 77 | 12 patents Advanced endoscopic imaging systems: ultrasonic, OCT, multi‑lumen, disposable, high‑gain compensation | — |
| 24 | Besun Biotechnology Developer of a synthetic biology-based platform for drug discovery | $15M | 46 mo ago | Seed | Kang Kang Co-Founder | — | — | — |
| 25 | Fuessen Developer of digital-based dental ecology platform | $14M | 77 mo ago | Series C | Yang Weizhen CEO | — | — | — |
| 26 | Pulsecare Medical Technology Developer of medical device solutions for heart and vascular care 22Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $14.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 22/100 | $14M | 7 mo ago | Series A | Javen Tan CEO | — | — | — |
| 27 | Zhixin Haozheng Developer of regenerative islets for the treatment of diabetes | $14M | 43 mo ago | Seed | — | — | — | — |
| 28 | Shenzhen Tianshen Medical Devices Provider of chemiluminescent diagnostic platform | $12M | 77 mo ago | Series B | — | 11 | — | — |
| 29 | ImmVira Developer of novel anti-cancer drug vectors | $10M | 43 mo ago | Series C | Grace Zhou Co-Founder & CEO | 18 | 76 patents Cancer immunotherapy: PD‑1 antibodies, oncolytic HSV for brain tumors, HER2‑targeting exosome miRNAs | — |
| 30 | Shenzhen Bowei Medical Robot Manufacturer of medical robots and related software for healthcare applications | $7M | 45 mo ago | Series B | — | 60 | — | — |
| 31 | Shenzhen Vienomics Bio Tech Provider of cancer screening technologies based on the gene sequencing technology and bioinformatics analysis | $7M | 91 mo ago | Deadpooled | Liu Chaoyu CEO | — | — | — |
| 32 | Shenzhen Rui Sheng Medical Technology Developer of stroke rehabilitation robot | $4M | 97 mo ago | Seed | Jing Wang Co-Founder | — | — | — |
| 33 | Xuanjia Group Operator of a sports platform providing live streams, video replays | $2M | 32 mo ago | Series A | Zhang Jiaheng Founder | 60 | — | — |
| 34 | Forward Pharma Developer of therapeutics for oncology and immunology | $1M | 34 mo ago | Series A | Liangliang Xu CEO | — | — | — |
Top 12 Life Sciences companies in Shenzhen
#1
Series D · Shenzhen, Guangdong Province · founded 2019$188.8Mraised▾
Series D · Shenzhen, Guangdong Province · founded 2019
Developer of medical robotic devices for rehabilitation and surgery. The company is developing medical robotic devices and equipment which enable physicians to improve the efficiency of surgical operations.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 16%Moat
top 31%Talent
bottom 49%News
bottom 41%Global
bottom 38%Market
bottom 28%Funding: Raised $189M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series D (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Nov 2025Series D$200M
- Jan 2025Series C$70M
- Jul 2023Series C$110.4M
- Nov 2021Series B$78.4M
Founders & team
Investors
Meituan, Dragon Ball Game, Lilly Asia Ventures, New World Development, Qiming Venture Partners, K2VC
Tech stack
Baidu Analytics (百度统计)GsapJqueryLayuiNginxOpen Graph
#2
Series A · Shenzhen, Guangdong Province · founded 2021$42.9Mraised▾
Series A · Shenzhen, Guangdong Province · founded 2021
Develope rof AI-based platform for cancer immunotherapy. It provides a Meta 10 Metabolism-enhanced cell treatment platform that encourages the metabolic reprogramming of exhausted T lymphocytes by oxidative phosphorylation, restoring their ability to proliferate and kill malignancies.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
AI
top 30%Talent
top 38%Funding
top 39%Global
bottom 29%Market
bottom 25%Tech
bottom 15%AI: Classified as an AI company · Product described with: ai-based
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $42.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Mar 2026)
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 awards · 1 expansions announced in 12 mo
Funding rounds
- Mar 2026Series A$29M
- Nov 2024Series A$13.9M
Founders & team
Investors
Jingtai Technology, Junyiinvestment, FUHO Capital Management, Zhongying Venture Capital, Tailong Investment, Zhongshan Venture Capital
Tech stack
Apache Http ServerBabelCore-JsPhp
#3
Seed · Shenzhen, Guangdong Province · founded 2012$28.5Mraised▾
Seed · Shenzhen, Guangdong Province · founded 2012
Developer of optical coherence tomography for coronary functional evaluation. The company focuses on the development of medical devices for minimally invasive interventional diagnosis and treatment using laser technology for clinical use.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 33%Talent
top 38%Global
bottom 36%Tech
bottom 34%Market
bottom 25%Funding: Raised $28.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 2 countries beyond China
Audience (LinkedIn): 868 LinkedIn followers
Funding rounds
- Mar 2026Seed$14.5M
- Mar 2024Seed$14M
Founders & team
Investors
Zhejiang Huarui Investment Holdings, Guangzhou Industrial Investment Group, HSG, BlueRun Ventures, Ant Group, CDH
Tech stack
Apache Http ServerBootstrapFancyboxFont AwesomeGoogle AnalyticsGoogle Tag Manager
#4
Series A · Shenzhen, Guangdong Province · founded 2021$14Mraised▾
Series A · Shenzhen, Guangdong Province · founded 2021
Developer of medical device solutions for heart and vascular care. The products and platforms uses technologies such as pulsed electric fields and ultrasound to provide treatments for various cardiovascular conditions.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 44%Talent
bottom 49%Market
bottom 37%Global
bottom 29%Funding: Raised $14.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series A (Nov 2025)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Nov 2025Series A$14M
- Aug 2024Series A—
Founders & team
Investors
Delian Capital, Tianfeng Capital, Oriza Holdings, Loayal Valley Capital, Tsinghua University
#5
Series C · Shenzhen, Guangdong Province · founded 2012$158Mraised▾
Series C · Shenzhen, Guangdong Province · founded 2012
Developer of genome sequencing technology for molecular diagnosis. The products include high-throughput gene sequencers, single-molecule gene sequencers, kits for non-invasive prenatal screening, preimplantation genetic testing, tumor, and genetic disease diagnosis. The company's technology includes sequencing optical systems, synthetic sequencing chemical systems, and sequencing chips.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 2.4% of this cohort's audience
Activity: 1 product launches announced in 12 mo
Funding rounds
- Aug 2023Series C$55.7M
- Sep 2021Series B$63.6M
- Jun 2021Series B$38.7M
Founders & team
Investors
Sansure, Cowin Capital, Guangzhou Jinyu Medical Testing Group, Shanghai Guoxin Investment Development, Shenzhen Gaoxintou Group, Tengye Ventures
Tech stack
All In One SeoCore-JsElementorGoogle AnalyticsGoogle Font ApiGoogle Tag Manager
#6
Series B · Shenzhen, Guangdong Province · founded 2014$56.7Mraised▾
Series B · Shenzhen, Guangdong Province · founded 2014
Developer of automated cell processing system. It offers the CellSep PRO system which uses gradient centrifugation for customized cell preparation. It also offers the EuLV system which is a stable cell line-based lentiviral vector production system used for cell and gene therapies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 413 LinkedIn followers
Funding rounds
- Feb 2024Series B$41.7M
- Jun 2022Series B$14.9M
Founders & team
Investors
Yuexiu Industrial Fund, Dachen Caizhi Venture Capital Management, Tasly, Asia Business Capital, Eight Roads Ventures
Tech stack
Apple Icloud MailBaidu Analytics (百度统计)Cookie ScriptGoogle AnalyticsGoogle Tag ManagerGsap
#7
Series B · Shenzhen, Guangdong Province · founded 2016 · 2805 employees$1Braised▾
Series B · Shenzhen, Guangdong Province · founded 2016 · 2805 employees
Provider of gene sequencing instruments, reagents, equipment, and related products. The company has multi-omics platforms which include robotic ultrasound systems, sequencers, and automation systems for life science research, agriculture, precision medicine, and healthcare. It also has sequencing reagents, enzymes, an instrument for microbial detection, analyzers, and others.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 139k LinkedIn followers — 51.2% of this cohort's audience
Funding rounds
- May 2020Series B$1B
- May 2019Series A—
Founders & team
Investors
IDG Capital, CPE, Huatai Zijin Investment, Titanium Capital, Shanghai Sailing, Huaxing New Economy Fund
#8
Series D · Shenzhen, Guangdong Province · founded 2015 · 700 employees$150.4Mraised▾
Series D · Shenzhen, Guangdong Province · founded 2015 · 700 employees
Provider of designing, manufacturing, regulatory affair, and other services for medical device industry
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers
Hiring: 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Regional Sales & Marketing Manager
Activity: 1 partnerships (incl. VitalAire) announced in 12 mo
Funding rounds
- Dec 2022Series D$71.7M
- Jan 2022Series C$78.7M
Investors
Shanghai Healthcare Capital, Xyzq, Next Capital, China New Town, Guangdong Chinese Medicine Healthcare Capital, Qianhai Ark Asset Management
Tech stack
Amazon SesAmazon Web ServicesIisJqueryMailgunMicrosoft Asp.Net
#9
Public · Shenzhen, Guangdong Province · founded 2017$306.7Mraised▾
Public · Shenzhen, Guangdong Province · founded 2017
Developer of surgical robot instruments. It manufactures surgical robots, devices and instruments for the healthcare sector. The companys products include robotic surgical systems for laparoscopic surgery, natural orifice surgery, and traditional invasive surgery.
Funding rounds
- Nov 2021Series C$200M
- Jan 2021Series B$92.6M
- Apr 2020Series A$14.1M
Founders & team
Investors
Sequoia Capital, Temasek, Boyu Capital, Mirae Asset, Orbimed, Sage Partners
Tech stack
Baidu Analytics (百度统计)HstsHttp/3JqueryLayuiNginx
#10
ICarbonX 🦄Series D · Shenzhen, Guangdong Province · founded 2015 · 300 employees$365.7Mraised▾
ICarbonX 🦄
Series D · Shenzhen, Guangdong Province · founded 2015 · 300 employees
iCarbonX provides a bioinformatics platform for health management and drug development. It plans to use big data and artificial intelligence to analyze omic data along with phenotypic, social, and environmental information. The analysis would be used by individuals for health management and by pharma companies for drug development. Solutions offered are Hey me, Healthtell immune response chip, and DigitalMe. Hey me is a digital health management platform that features genetic testing, sports data tracking, prediction, customized sports programs, personalized beauty products according to skin type, personalized dietary plans. DigitalMe is a health platform that tracks the health of patients suffering from chronic disease.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Moat
top 26%Funding
top 27%Talent
top 28%AI
top 30%Market
top 38%Global
bottom 48%Moat: Editorial + unicorn rating 9/10 · Unicorn · 9 curated direct competitors tracked
Funding: Raised $366M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series D (Apr 2021)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. AI Health Institute (AIHI)) announced in 12 mo
Funding rounds
- Apr 2021Series D$151M
- 2018Series A—
- Jul 2016Series A$45M
- Apr 2016Series A$154.7M
Founders & team
Investors
Vcanbio Cell & Gene Engineering Corporation, China Money Network, China Investment Corporation, China Bridge Capital, Tencent, Wealthking Investments
Tech stack
FlexsliderJqueryMicrosoft 365Nginx
#11
Public · Shenzhen, Guangdong Province · founded 1999 · 7 employees$300.4Mraised▾
Public · Shenzhen, Guangdong Province · founded 1999 · 7 employees
Provider of services in genome sequencing. The company provides services in large-scale sequencing of human, plant, and animal genome. The company's major scientific accomplishments include sequencing the genome of an Asian person, the giant panda, and the human gut microbiome. It also contributed to the Human Genome Project and the rice-genome-sequencing initiative. The company's sequencing platform includes BGIseq.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 95k LinkedIn followers — 35.2% of this cohort's audience
Activity: 1 product launches · 1 partnerships (incl. Universidade Católica de Braslia) announced in 12 mo
Funding rounds
- Feb 2021Post IPO$300M
- Jan 2015Grant (prize money)$350.7K
Founders & team
Investors
Europa, SDIC, Jinsheng Capital Management, Share Capital, MSA Capital, NLVC
Tech stack
Alibaba Cloud CdnCloudflareCloudflare Bot ManagementCore-JsGoogle Tag ManagerHsts
#12
Series B · Shenzhen, Guangdong Province · founded 2016 · 400 employees$88.5Mraised▾
Series B · Shenzhen, Guangdong Province · founded 2016 · 400 employees
Developer of protein and antibody drugs to treat multiple diseases. It focuses on the research and development of antibodies, vaccines, and recombinant proteins, for the treatment of tumors, cardiovascular and cerebrovascular diseases, allergic diseases, etc.
Funding rounds
- Jan 2023Series B$88.5M
Investors
Chengtong Private Equity Fund Management, CCB Capital Management, Guolian Group, China Chengtong, National Research Fund, Yueke Fund
Funding & investor landscape
$3.4Btotal disclosed funding
34companies funded
55disclosed rounds
1rounds last 90 days
Most active investors
Qiming Venture Partners6 rounds
Notable founders
Zerui Wang
Co-Founder · Cornerstone Robotics
Li Tang
Co-Founder · Leman Biotech
Yugang Guo
Co-Founder · Leman Biotech
Zhu Rui
Founder & CEO · Vivolight
Ray
CEO · Vivolight
Javen Tan
CEO · Pulsecare Medical Technology
Yan Qin
CEO · GeneMind
Xue Bofu
Founder · Shenzhen Shenyan Biotechnology
Ma Mo
CEO · Shenzhen Shenyan Biotechnology
Liu Siqi
Co-Founder · MGI
Yang Huanming
Co-Founder · MGI
Gao Yuanqian
Co-Founder · Shenzhen Jingfeng Medical Technology
Prism market signals · China · country-scoped Prism corpus, 217,045 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN SHENZHEN · Health & Bio
How research on Biotechnology in Shenzhen is moving
A read on the academic research around Biotechnology in Shenzhen — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 151 papers.
Shenzhen University and allied institutes lead optimistic research (mean stance 0.56) dominated by cancer nanoplatforms and CRISPR engineering, with breakthroughs outnumbering concerns 72 to 17.
151 papers · stance +0.56 · 54% breakthrough · 13% concern
top institutions
- Shenzhen University32
- Agricultural Genomics Institute at Shenzhen30
- Shenzhen Institutes of Advanced Technology18
- Chinese University of Hong Kong, Shenzhen10
- Shenzhen University Health Science Center6
leading researchers
Fang Wang · Jihang Chen · Ali Raza · Binglin Shen · Chao Liu · Chengye Zhao
prism intelligence · tone & topics
94% positive · 4% critical tone
HealthPharmaceuticalsAgricultureMedical ResearchGeneticsBiology
▲
Breakthroughs72 · 48%
▼ 50%→46% share
▼0.9× share momentum0 median citations88% since 2021mostly methods-led
Gene research newly emerged with 9 papers, while In vivo studies quadrupled, signaling intensifying molecular-level breakthroughs.
rising sub-themes (early→recent)
- In vivo1→4
Newly emergingGene 0→9 · Mutant 0→4 · Detection limit 0→4
Landmark Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy · 991 cites
◆
Advancements45 · 30%
▲ 0%→32% share
0 median citations96% since 2021mostly empirical
Advancements segment surged from 0% to 32% field-share, with Gene and Epigenetics newly emerging across 4 papers each.
rising sub-themes (early→recent)
- Gene4
- Epigenetics4
- In vitro3
- Nutrient3
- Agriculture3
Newly emergingGene 0→4 · Epigenetics 0→4 · In vitro 0→3
Landmark Cytokines: From Clinical Significance to Quantification · 857 cites
▼
Concerns17 · 11%
▼ 50%→10% share
▼0.2× share momentum0 median citations82% since 2021mostly reviews
Concerns field-share collapsed from 50% to 10%, yet Antibiotic resistance newly emerged with 4 rising papers.
rising sub-themes (early→recent)
- Agriculture4
- Antibiotic resistance4
- Identification (biology)3
- Gene2
- Microplastics2
Newly emergingAgriculture 0→4 · Antibiotic resistance 0→3
Landmark A chemical genetic roadmap to improved tomato flavor · 804 cites
Common questions
How many Life Sciences companies are there in Shenzhen, China?
Radar tracks 124 indexable Life Sciences companies headquartered in Shenzhen, China that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Shenzhen, China?
The Life Sciences companies in Shenzhen, China on this list have raised a combined $3.4B in disclosed equity funding across 34 funded companies.
Which is the highest-funded Life Sciences company in Shenzhen, China?
MGI is the highest-funded Life Sciences company in Shenzhen, China, with $1B in disclosed equity funding.
How many Life Sciences companies in Shenzhen, China are funded?
34 of the 124 Life Sciences companies in Shenzhen, China on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Shenzhen, China?
1 Life Sciences company in Shenzhen, China on this list is valued at $1B or more.
Who are the top investors in Shenzhen, China Life Sciences companies?
The most active investors in Shenzhen, China Life Sciences companies on this list include Cowin Capital, Shenzhen Capital Group, ASB Ventures, BGI Co-win, Qiming Venture Partners.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.